Lipid lowering for secondary prevention of cardiovascular disease in older adults

Drugs and Aging

Volumn 27, Issue 12, 2010, Pages 959-972

  Thomas, Joseph E ^a   Tershakovec, Andrew M ^b   Jones Burton, Charlotte ^b   Sayeed, Reza A ^c   Foody, Joanne M ^d  

^a UNIVERSITY OF KENTUCKY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Bioscript Stirling Ltd   (United Kingdom)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antihyperlipidaemics, therapeutic use; Bile acid binding protein modulator, therapeutic use; Cardiovascular disorders, prevention; Elderly; Ezetimibe, therapeutic use; Fibric acid derivatives, therapeutic use; HMG CoA reductase inhibitors, therapeutic use; Hyperlipidaemia, treatment; Niacin, therapeutic use

Indexed keywords

ATORVASTATIN; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FLUINDOSTATIN; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE HEART INFARCTION; AMINOTRANSFERASE BLOOD LEVEL; BRAIN HEMORRHAGE; CANCER INCIDENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY RECANALIZATION; DRUG ABSORPTION; DRUG EFFECT; DRUG RELEASE; DRUG SAFETY; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INJURY; LIVER TOXICITY; MEDLINE; NEOPLASM; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION;

EID: 78649351912     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11539550-000000000-00000     Document Type: Review

References (74)

1. World Health Organization. Fact sheet no. 317. Cardiovascular diseases [online]. Available from URL: http://www. who.int/mediacentre/factsheets/fs317/ en/index.html [Accessed 2010 Mar 19]
2. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: e21-181
3. Ford ES, Giles WH, Mokdad AH. The distribution of 10-year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III. J Am Coll Cardiol 2004 May; 43 (10): 1791-6
4. Manolio TA, Pearson TA, Wenger NK, et al. Cholesterol and heart disease in older persons and women: review of an NHLBI workshop. Ann Epidemiol 1992 Jan-Mar; 2 (1-2): 161-76
5. Kronmal RA, Cain KC, Ye Z, et al. Total serum cholesterol levels and mortality risk as a function of age: a report based on the Framingham data. Arch Intern Med 1993 May; 153 (9): 1065-73
6. Strandberg TE, Strandberg A, Rantanen K, et al. Low cholesterol, mortality, and quality of life in old age during a 39-year follow-up. J Am Coll Cardiol 2004; 44 (5): 1002-8
7. Wenger NK. Dyslipidemia as a risk factor at elderly age. Am J Geriatr Cardiol 2004 May-Jun; 13 (3 Suppl. 1): 4-9
8. Rubin SM, Sidney S, Black DM, et al. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann Intern Med 1990 Dec; 113 (12): 916-20
9. Benfante R, Reed D, Frank J. Do coronary heart disease risk factors measured in the elderly have the same predictive roles as in the middle aged: comparisons of relative and attributable risks. Ann Epidemiol 1992 May; 2 (3): 273-82
10. Amarenco P, Steg PG. The paradox of cholesterol and stroke. Lancet 2007 Dec; 370 (9602): 1803-4
11. Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet 2007 Dec; 370 (9602): 1829-39
12. Curb JD, Abbott RD, Rodriguez BL, et al. High density lipoprotein cholesterol and the risk of stroke in elderly men: the Honolulu Heart Program. Am J Epidemiol 2004 Jul; 160 (2): 150-7
13. National Cholesterol Education Program. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 Dec; 106 (25): 3143-421
14. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004 Apr; 291 (15): 1864-70
15. Cournot M, Cambou JP, Quentzel S, et al. Key factors associated with the under-prescription of statins in elderly coronary heart disease patients: results from the ELIAGE and ELICOEUR surveys. Int J Cardiol 2006; 111: 12-8
16. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005 Oct; 366 (9493): 1267-78
17. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008 Jan; 371 (9607): 117-25
18. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002 Nov; 360 (9346): 1623-30
19. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008 Nov; 359 (21): 2195-207
20. Poulter NR, Dahlof B, Sever PS, et al. Impact of atorvastatin on cardiovascular events in 2440 men and women aged 65 years and above: evidence from the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) [abstract]. Stroke 2006; 37: 695
21. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003 Apr; 361 (9364): 1149-58
22. Neil HA, DeMicco DA, Luo D, et al. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care 2006 Nov; 29 (11): 2378-84
23. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004 Aug; 364 (9435): 685-96
24. Amarenco P, Bogousslavsky J, Callahan 3rd A, et al. Highdose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006 Aug; 355 (6): 549-59
25. Chaturvedi S, Zivin J, Breazna A, et al. Effect of atorvastatin in elderly patients with a recent stroke or transient is-chemic attack. Neurology 2009 Feb; 72 (8): 688-94
26. Ali R, Alexander KP. Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence. Am J Geriatr Pharmacother 2007 Mar; 5 (1): 52-63
27. Robinson JG, Bakris G, Torner J. Is it time for a cardiovascular primary prevention trial in the elderly? Stroke 2007 Feb; 38 (2): 441-50
28. Robinson JG. Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly: opportunities and challenges. Drugs Aging 2009 Nov; 26 (11): 917-31
29. Goldstein LB, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008 Jun; 70 (24 Pt 2): 2364-70
30. Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients: a hierarchical Bayesian metaanalysis. J Am Coll Cardiol 2008 Jan; 51 (1): 37-45
31. Welch HG, Albertsen PC, Nease RF, et al. Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med 1996 Mar; 124 (6): 577-84
32. Tinetti ME, McAvay GJ, Fried TR, et al. Health outcome priorities among competing cardiovascular, fall injury, and medication-related symptom outcomes. J Am Geriatr Soc 2008 Aug; 56 (8): 1409-16
33. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004 Jul; 110 (2): 227-39
34. Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 2001 May; 134 (10): 931-40
35. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterollowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997 Dec; 96 (12): 4211-8
36. Mevacor® (lovastatin) tablets: US prescribing information. Whitehouse Station (NJ): Merck 2008 [online]. Available from URL: http://www.merck.com/ product/usa/pi-circulars/m/mevacor/mevacor-pi.pdf [Accessed 2010 Mar 19]
37. Zocor® (simvastatin) tablets: US prescribing information. Whitehouse Station (NJ): Merck 2008 [online]. Available from URL: http://www.merck.com/ product/usa/pi-circulars/z/zocor/zocor-pi.pdf [Accessed 2010 Mar 19]
38. Lipitor® (atorvastatin calcium) tablets: US prescribing information. Dublin: Pfizer 2009 [online]. Available from URL: http://www.pfizer.com/files/ products/uspi-lipitor.pdf [Accessed 2010 Mar 19]
39. Crestor® (rosuvastatin calcium): US prescribing information. Wilmington (DE): AstraZeneca 2009 [online]. Available from URL: http://www1.astrazeneca-us.com/pi/crestor.pdf [Accessed 2010 Mar 19]
40. Lescol® (fluvastatin sodium) capsules and Lescol® XL (fluvastatin sodium) extended-release tablets: US prescribing information. East Hanover (NJ): Novartis 2006 [online]. Available from URL: http://www.pharma.us.novartis. com/product/pi/pdf/Lescol.pdf [Accessed 2010 Mar 19]
41. Pravachol® (pravastatin sodium) tablets: US prescribing information. Princeton (NJ): Bristol-Myers Squibb 2007 [online]. Available from URL: http://packageinserts.bms. com/pi/pi-pravachol.pdf [Accessed 2010 Mar 19]
42. Pasternak RC, Smith Jr SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002 Aug; 106 (8): 1024-8
43. McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006 Apr; 97 (8A): 89C-94C
44. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006 Dec; 80 (6): 565-81
45. Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol 2007 May; 49 (17): 1753-62
46. Brass LM, Alberts MJ, Sparks L. An assessment of statin safety by neurologists. Am J Cardiol 2006 Apr; 97 (8A): 86C-8C
47. National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 May; 285 (19): 2486-97
48. Davidson MH. The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opin Pharma-cother 2007 Oct; 8 (15): 2569-78
49. Jacobson TA, Armani A, McKenney JM, et al. Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol 2007 Mar; 99 (6A): 47C-55C
50. Florentin M, Liberopoulos EN, Mikhailidis DP, et al. Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Curr Med Res Opin 2008 Apr; 24 (4): 995-1009
51. Welchol™ (colesevelam hydrochloride): US prescribing information. Parsippany (NJ): Daiichi Sankyo 2008 [online]. Available from URL: http://www.welchol.com/pdf/Welchol- PI.pdf [Accessed 2010 Mar 19]
52. Pearson TA, Denke MA, McBride PE, et al. A communitybased, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-on to Statin for Effectiveness (EASE) trial. Mayo Clin Proc 2005 May; 80 (5): 587-95
53. Pearson T, Denke M, McBride P, et al. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial. Am J Geriatr Pharmacother 2005 Dec; 3 (4): 218-28
54. Robinson JG, Davidson MH, Shah A, et al. Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65-74 and 75 years and older. Aging Health 2007; 3: 691-705
55. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008 Apr; 358 (14): 1431-43
56. Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008 Dec; 52 (25): 2198-205
57. Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008; 156 (5): 826-32
58. Califf RM, Lokhnygina Y, Cannon CP, et al. An update on the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J 2010 May; 159 (5): 705-9
59. Zetia® (ezetimibe): US prescribing information. North Wales (PA): Merck/Schering-Plough Pharmaceuticals 2009 [online]. Available from URL: http://www.zetia.com/zetia/shared/documents/zetia-pi.pdf [Accessed 2010 Mar 19]
60. Kashani A, Sallam T, Bheemreddy S, et al. Review of sideeffect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol 2008 Jun; 101 (11): 1606-13
61. Davidson MH, Maccubbin D, Stepanavage M, et al. Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol 2006 Jan; 97 (2): 223-8
62. Stein EA, Ballantyne CM, Windler E, et al. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 2008 Feb; 101 (4): 490-6
63. Feldman T, Davidson M, Shah A, et al. Low density lipoprotein lowering efficacy of the ezetimibe/simvastatin combination tablet in a large cohort of elderly patients with primary hypercholesterolemia [abstract]. J Am Geriatr Soc 2005; 53 (4 Suppl.): S78-9
64. Abate N, Ballantyne CM, Catapano AL, et al. LDL-C lowering efficacy of the ezetimibe/simvastatin single tablet compared with atorvastatin or rosuvastatin in elderly patients with hypercholesterolemia [abstract]. J Am Geriatr Soc 2006; 54 (4 Suppl.): S163
65. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008 Sep; 359 (13): 1343-56
66. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008 Sep; 359 (13): 1357-66
67. SHARP Collaborative Group: Study of Heart and Renal Protection (SHARP). Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. Epub 2010 Sep 20; doi: 10.1016/j.ahj.2010.08.012
68. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986 Dec; 8 (6): 1245-55
69. Berge KG, Canner PL. Coronary drug project: experience with niacin. Coronary Drug Project Research Group. Eur J Clin Pharmacol 1991; 40 Suppl. 1: S49-51
70. McCormack PL, Keating GM. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs 2005; 65 (18): 2719-40
71. Niaspan® (niacin extended-release tablets): US prescribing information. North Chicago (IL): Abbott Laboratories 2009 [online]. Available from URL: http://www.rxabbott. com/pdf/niaspan.pdf [Accessed 2010 Mar 19]
72. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999 Aug; 341 (6): 410-8
73. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005 Nov; 366 (9500): 1849-61
74. Meade T, Zuhrie R, Cook C, et al. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002 Nov; 325 (7373): 1139